专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

81. 发明公开

KR1020090081758A 생체물질 검출 또는 분석용 입자, 이것을 포함하는 조성물및 이것의 제조방법 有权
标题翻译：用于生物分子检测或分析的颗粒，具有该生物分子的组合物及其制备方法
公开(公告)号：KR1020090081758A
公开(公告)日：2009-07-29
申请号：KR1020080007810
申请日：2008-01-25
申请人： 엘지전자 주식회사
发明人： 임귀삼 , 구윤희 , 조성문 , 홍형기 , 권성훈 , 박욱
IPC分类号： A61K9/14 , G01N33/48 , G01N33/544 , B82B1/00
CPC分类号： A61K9/146 , A61K49/00 , A61K2039/625 , B82Y5/00 , G01N33/544
摘要： A particle for detecting and analyzing a bio material, composition containing the same and manufacturing method are provided to enhance the binding property of particle with bio material and have particle which is mechanically and chemically stable. A method for manufacturing the composition having a particle for detecting and analyzing a bio material comprises: a step of mixing the bio material having a biotin with a nano bead which is coated with streptavidin and combining the biotin and streptavidin (S210); a step of mixing with a hydrogel (S220); a step of combining the biomaterial(130) having biotin(131) with nano bead(120) in which streptavidin(121) is coated; and a step of adding the hydrogel(110) to produce a bio complex particle composition(201).
摘要翻译：提供用于检测和分析生物材料的颗粒，含有该颗粒的组合物和制造方法，以增强颗粒与生物材料的结合性质，并具有机械和化学稳定的颗粒。制备具有用于检测和分析生物材料的颗粒的组合物的方法包括：将具有生物素的生物材料与涂覆有链霉抗生物素蛋白并结合生物素和链霉亲和素的纳米珠混合的步骤（S210）; 与水凝胶混合的步骤（S220）; 将具有生物素（131）的生物材料（130）与其中涂覆有链霉亲和素（121）的纳米珠（120）组合的步骤; 以及添加水凝胶（110）以生成生物复合物颗粒组合物（201）的步骤。

82. 发明公开

KR1020090031618A 나노입자형 모다피닐 제제 无效
标题翻译： MODAFINIL的纳米制剂配方
公开(公告)号：KR1020090031618A
公开(公告)日：2009-03-26
申请号：KR1020097002834
申请日：2007-07-12
申请人： 엘란 파마 인터내셔널 리미티드
发明人： 젠킨스,스코트 , 리버시즈,게리 , 맨서,데이비드
IPC分类号： A61K9/14 , B82Y5/00 , A61K31/165 , A61P25/28
CPC分类号： A61K9/145 , A61K9/146
摘要： The present invention is directed to compositions comprising a nanoparticulate modafinil compositions, or a salt(s), or an enantiomer(s), or a prodrug(s), or a polymorph(s) or derivative thereof, having improved bioavailability. The nanoparticulate modafinil composition formulation particles of the composition have an effective average particle size of less than about 2000 nm and are useful in the treatment of dyssomnias, including but not limited to, narcolepsy, chronic fatigue, eating disorders, compulsive behaviors, ADHD, addictions, substance abuse, sleepiness, nervous system diseases, conditions, syndromes, and symptoms and related diseases, conditions, and symptoms.
摘要翻译：本发明涉及包含具有改善的生物利用度的纳米颗粒莫达非尼组合物或其一种或多种或多种或多种或多种或多种或多种多晶型物或其衍生物的组合物。组合物的纳米微粒莫达非尼组合物制剂颗粒具有小于约2000nm的有效平均粒度，并且可用于治疗睡眠障碍，包括但不限于发作性睡病，慢性疲劳，进食障碍，强迫行为，ADHD，成瘾，药物滥用，嗜睡，神经系统疾病，病症，综合征，症状及相关疾病，病症和症状。

83. 发明公开

KR1020080059400A 약물 전달 체계 有权
标题翻译：药物递送系统
公开(公告)号：KR1020080059400A
公开(公告)日：2008-06-27
申请号：KR1020087009770
申请日：2006-10-25
申请人： 에보니크 룀 게엠베하
发明人： 자일러,마티아스 , 빈다브,노르베르트 , 스티클러,만프레드 , 페터라이트,한스-울리히
IPC分类号： A61K47/30 , A61K47/48 , A61K9/16
CPC分类号： A61K9/146 , A61K9/1641 , A61K47/34 , A61K47/59 , A61K47/595 , A61K47/62 , A61K47/30 , A61K9/16 , A61K47/50
摘要： The invention relates to novel particulate drug-delivery systems based on a polymer support containing at least one linear, branched or cross-linked polymer in a fraction of over 50 percent by weight in relation to the total weight of the support. The system is characterised in that at least one signal substance for transport through a biological barrier and at least one active ingredient are stored, the support, signal substance and active ingredient having no covalent links and no active-ingredient specific and signal substance specific coordinative links between one another.
摘要翻译：本发明涉及基于聚合物载体的新型颗粒药物递送系统，其包含至少一种相对于载体总重量超过50重量％的直链，支链或交联聚合物。该系统的特征在于，存储用于传输通过生物屏障和至少一种活性成分的至少一种信号物质，所述载体，信号物质和没有共价连接并且没有活性成分特异性和信号物质特异性协调链接的信号物质和活性成分在彼此之间

84. 发明公开

KR1020080034166A 감각기관 수용성 이부프로펜 경구 투약 제형 및 동일물의제조 및 사용 방법 无效
标题翻译：有机可接受的IBUPROFEN口服制剂，其制备方法和使用方法
公开(公告)号：KR1020080034166A
公开(公告)日：2008-04-18
申请号：KR1020087004052
申请日：2006-10-17
申请人： 테이코쿠 팔마 유에스에이, 인코포레이티드
发明人： 히비,토루
IPC分类号： A61K9/28 , A61K47/08 , A61K47/12 , A61K31/19
CPC分类号： A61K9/145 , A61K9/0056 , A61K9/146 , A61K31/192 , A61K31/724 , A61K36/534 , A61K2300/00
摘要： Organoleptically acceptable solid oral dosage formulations of ibuprofen, and methods of making and using the same, are provided. A feature of the subject formulations is that they include ibuprofen and a masking component. In certain embodiments, the masking component includes one or more of a cooling agent, an organic acid and a cyclodextrin. The subject invention finds use in a variety of applications.
摘要翻译：提供布洛芬的感觉可接受的固体口服剂量制剂及其制备和使用方法。主题制剂的特征在于它们包括布洛芬和掩蔽组分。在某些实施方案中，掩蔽组分包括冷却剂，有机酸和环糊精中的一种或多种。本发明可用于各种应用。

85. 发明公开

KR1020080017065A 나노입자형 아세트아미노펜 제제 无效
标题翻译：纳米脂肪酸乙酰胺制剂
公开(公告)号：KR1020080017065A
公开(公告)日：2008-02-25
申请号：KR1020077030960
申请日：2006-06-05
申请人： 엘란 파마 인터내셔널 리미티드
发明人： 젠킨스스콧 , 리버사이쥐게리쥐.
IPC分类号： A61K9/16 , A61K31/165 , A61K9/14 , B82Y5/00
CPC分类号： A61K9/145 , A61K9/146 , A61K31/167
摘要： The invention is directed to compositions comprising a nanoparticulate acetaminophen composition, or a salt or derivative thereof, having improved bioavailability. The nanoparticulate acetaminophen particles of the composition have an effective average particle size of less than about 2000 nm and are useful in the treatment of aches and pain, and in the reduction of fever and related conditions.
摘要翻译：本发明涉及包含具有改善的生物利用度的纳米微粒对乙酰氨基酚组合物或其盐或衍生物的组合物。组合物的纳米微粒对乙酰氨基酚颗粒具有小于约2000nm的有效平均粒度，并且可用于治疗疼痛和降低发烧及相关病症。

86. 发明公开

KR1020070112217A 비결정질 로시글리타존을 포함하는 제약 조성물 无效
标题翻译：包含非晶罗西他他的药物组合物
公开(公告)号：KR1020070112217A
公开(公告)日：2007-11-22
申请号：KR1020077021885
申请日：2006-02-23
申请人： 글락소스미스클라인 엘엘씨
发明人： 크레이그,앤드류,시몬 , 크로웨,데이비드 , 호,팀,치엔,팅 , 밀란,마이클,존
IPC分类号： A61K9/14 , A61K31/4427 , A61P3/10
CPC分类号： A61K9/146 , A61K9/5138 , A61K9/5161 , A61K9/5192 , A61K9/70 , A61K31/00 , A61K31/4439 , D01D5/003 , D01F1/10
摘要： The present invention is directed to use of electrospinning, i.e. the process of making polymer nanofibers from either a solution or melt under electrical forces, to prepare stable, solid dispersions of amorphous drugs in polymer nanofibers. The present invention is also directed to the process of making solid dispersions of amorphous forms and compositions of rosiglitazone and its pharmaceutically acceptable salts.
摘要翻译：本发明涉及静电纺丝的应用，即在电力下由溶液或熔体制备聚合物纳米纤维的方法，以在聚合物纳米纤维中制备稳定的无定形药物的固体分散体。本发明还涉及制备无定形形式的固体分散体和罗格列酮及其可药用盐组合物的方法。

87. 发明公开

KR1020070112164A 나노입자형 벤조디아제핀의 에어로졸과 주사가능한 제제 无效
标题翻译：纳米颗粒苯并咪唑的喷雾剂和注射剂配方
公开(公告)号：KR1020070112164A
公开(公告)日：2007-11-22
申请号：KR1020077020820
申请日：2006-02-15
申请人： 엘란 파마 인터내셔널 리미티드
发明人： 리버사이쥐게리 , 젠킨스스콧
IPC分类号： A61K9/14 , A61K9/10
CPC分类号： A61K31/5513 , A61K9/0019 , A61K9/0043 , A61K9/0073 , A61K9/145 , A61K9/146
摘要： Described are nanoparticulate formulations of a benzodiazepine, such as lorazepam, that does not require the presence of polyethylene glycol and propylene glycol as stabilizers, and methods of making and using such formulations. The formulations are particularly useful in aerosol and injectable dosage forms, and comprise nanoparticulate benzodiazepine, such as lorazepam, and at least one surface stabilizer. The formulations are useful in the treatment of status epilepticus, treatment of irritable bowel syndrome, sleep induction, acute psychosis, and as a pre-anesthesia medication.
摘要翻译：描述的是不需要存在聚乙二醇和丙二醇作为稳定剂的苯并二氮杂，例如劳拉西泮的纳米颗粒制剂，以及制备和使用这些制剂的方法。制剂特别可用于气雾剂和可注射剂型，并且包含纳米颗粒苯二氮卓类，例如劳拉西泮和至少一种表面稳定剂。该制剂可用于治疗癫痫持续状态，治疗肠易激综合征，睡眠诱导，急性精神病以及作为麻醉前药物。

88. 发明授权

KR100767349B1 페노피브레이트를 함유하는 경구용 약제 조성물 및 그의제조방법 有权
标题翻译：用于口服包含芬太尼的药物组合物及其制备方法
公开(公告)号：KR100767349B1
公开(公告)日：2007-10-17
申请号：KR1020060072550
申请日：2006-08-01
申请人： 삼천당제약주식회사
发明人： 백승희 , 한성균 , 신은종 , 이우영 , 박준석
IPC分类号： A61K9/10 , A61K9/14 , A61P3/06
CPC分类号： A61K9/146 , A61K9/1617 , A61K9/1635 , A61K9/1652 , A61K31/216
摘要： An oral pharmaceutical composition comprising fenofibrate and a preparation method thereof are provided to improve bioavailability of fenofibrate by increasing its solubility and reduce preparation time by rapidly drying effective ingredients through spray drying. An oral pharmaceutical composition for treating hyperlipidemia comprises solid dispersion containing amorphous fenofibrate which is prepared by dispersing 1 part by weight of amorphous fenofibrate in 0.2-2.0 parts by weight of water-soluble polymer and 0.1-0.5 parts by weight of surfactant, wherein the water-soluble polymer is selected from hydroxypropylcellulose, hydroxypropylmethylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, hydroxybutylcellulose, hydroxypentylcellulose, hydroxypropylbutylcellulose, hydroxypropylalkylcellulose, polyvinylpyrrolidone and polyvinylalcohol; and the surfactant is monooleic acid ester, monolaurylic acid ester, monopalmitic acid ester, monostearic acid ester, polyoxyethylene sorbitan ester, sodium dioctylsulfosuccinic acid, lecithin, stearylalcohol, cetostearylalcohol, cholesterol, polyoxyethylene lysine oil, polyoxyethylene fatty acid glyceride, poloxamer and cremophor.
摘要翻译：提供包含非诺贝特的口服药物组合物及其制备方法，以通过通过喷雾干燥快速干燥有效成分来提高非诺贝特的溶解度并缩短制备时间来提高非诺贝特的生物利用度。一种用于治疗高脂血症的口服药物组合物，包括含非晶非诺贝特的固体分散体，其通过将1重量份无定形非诺贝特分散在0.2-2.0重量份水溶性聚合物和0.1-0.5重量份表面活性剂中制备，其中水可溶性聚合物选自羟丙基纤维素，羟丙基甲基纤维素，羟甲基纤维素，羟乙基纤维素，羟丁基纤维素，羟戊基纤维素，羟丙基丁基纤维素，羟丙基烷基纤维素，聚乙烯吡咯烷酮和聚乙烯醇; 表面活性剂为单油酸酯，单月桂酸酯，单棕榈酸酯，单硬脂酸酯，聚氧乙烯脱水山梨糖醇酯，二辛基磺基琥珀酸钠，卵磷脂，硬脂醇，十六醇十八醇，胆固醇，聚氧乙烯赖氨酸油，聚氧乙烯脂肪酸甘油酯，泊洛沙姆和cremophor。

89. 发明授权

KR100760764B1 수용성, 수난용성 또는 수불용성 활성 화합물의 고형제제의 제조 방법 失效
标题翻译：水溶性，微溶于水或不溶于水的活性化合物的固体制剂的生产
公开(公告)号：KR100760764B1
公开(公告)日：2007-10-04
申请号：KR1020010074554
申请日：2001-11-28
申请人： 바스프 에스이
发明人： 오우베터,헬무트 , 본,헤리베르트 , 뤼데케,에릭 , 힌츠,빌리 , 룬제,프란크 , 파이퍼,안젤리카-마리아
IPC分类号： B01J2/08 , B82Y40/00
CPC分类号： A61Q1/12 , A23K20/174 , A23K20/179 , A23K40/00 , A23K40/10 , A23K40/20 , A23K40/25 , A23K40/30 , A23L5/44 , A23L33/155 , A23P10/40 , A23V2002/00 , A61K8/11 , A61K8/31 , A61K8/35 , A61K9/146 , A61K9/1658 , A61K9/5169 , A61K31/522 , A61K2800/412 , A23V2250/54246 , A23V2250/213 , A23V2250/211
摘要： 본 발명에서는 식품 및 동물 사료 부문 또는 약품 및 화장품 용도에 적합한 적어도 1종의 수용성, 수난용성 또는 수불용성 활성 화합물의 고형 제제를 제조하기 위한 방법을 기재한다. 또한, 본 발명은 상기 제제가 분산상으로서 존재하는 유성 현탁액, 및 상기 제제의 동물 사료, 식품, 약품 및 화장품 제제의 첨가제로서의 용도에 관한 것이다.
수용성, 수난용성 또는 수불용성 활성 화합물, 고형 제제, 유성 현탁액, 동물 사료, 식품, 약품, 화장품, 분산상
摘要翻译：描述了一种制备至少一种适用于食品和动物饲料领域或用于药物和化妆品应用的水溶性，微水溶性或水不溶性活性化合物的固体制剂的方法。此外，本发明涉及这些制剂作为分散相存在的油性悬浮液，以及这些制剂作为动物饲料，食品，药物和化妆品制剂的添加剂的用途。

90. 发明公开

KR1020070094898A 주사가능한 나노입자형 올란자핀 제형 有权
标题翻译：可注射的纳米制剂奥兰治泊配方
公开(公告)号：KR1020070094898A
公开(公告)日：2007-09-27
申请号：KR1020077013288
申请日：2005-11-16
申请人： 엘커메스 파마 아일랜드 리미티드
发明人： 리버시지게리 , 젠킨스스콧
IPC分类号： A61K9/51 , A61K9/14 , A61K31/551 , A61K9/22
CPC分类号： A61K9/145 , A61K9/0019 , A61K9/146 , A61K9/148 , A61K31/551 , Y10S977/902 , Y10S977/904 , Y10S977/905 , Y10S977/906 , Y10S977/915
摘要： Described are injectable formulations of nanoparticulate olanzapine that produce a prolonged duration of action upon administration, and methods of making and using such formulations. The injectable formulations comprise nanoparticulate olanzapine.
摘要翻译：描述了纳米颗粒奥氮平的可注射制剂，其在给药时产生延长的作用持续时间，以及制备和使用这些制剂的方法。可注射制剂包含纳米颗粒奥氮平。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式